Market Cap 22.27B
Revenue (ttm) 982.02M
Net Income (ttm) -416.28M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -42.39%
Debt to Equity Ratio -8.30
Volume 3,455,300
Avg Vol 2,750,666
Day's Range N/A - N/A
Shares Out 132.60M
Stochastic %K 90%
Beta 1.59
Analysts Strong Sell
Price Target $149.17

Company Profile

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tumor DNA to detect cancer at the molecular level; and Guardant360 Tissue test, a molecular profiling t...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 855 698 8887
Fax: 888 974 4258
Address:
3100 Hanover Street, Palo Alto, United States
Intelligent_investor_
Intelligent_investor_ Jul. 4 at 3:26 PM
$TEM My screener tells me Tempus AI is a buy. So I will be buying 🙉 $GH $NTRA
0 · Reply
Snozz
Snozz Jul. 4 at 3:58 AM
$GH Shield Multi-Cancer Detection to be offered in India. Looks like under license for 10 different cancers. https://www.indiatoday.in/health/story/multi-cancer-blood-test-india-zydus-apollo-shield-mcd-10-cancers-2939850-2026-07-03
0 · Reply
NasdaqNavigatorrr
NasdaqNavigatorrr Jul. 3 at 9:58 PM
Rotation into $XBI has been strong, but this looks more extended than fresh. Biotech momentum is there, but when everyone crowds the move, risk/reward starts to tighten. We closed $GH Wednesday as balancing the book got tougher.
0 · Reply
WallStreetGrowth
WallStreetGrowth Jul. 3 at 9:04 PM
$GH Bernstein lifts target to $200 from $175 after $UNH agreed to cover Shield, Guardant’s blood-based colorectal cancer screening for adults 45+. Big deal for adoption here — coverage removes a major hurdle. Outperform unchanged.
0 · Reply
WAJeff
WAJeff Jul. 3 at 6:26 PM
Top 50 realized gainer changes: $GH (64.2% ytd) climbed to #37, bumping $CIEN and others down the list. $NXT (28.18% ytd) falls out of the top 50
0 · Reply
MorganHoratio
MorganHoratio Jul. 2 at 9:57 PM
One of the strongest sectors outside of AI right now is Biotech. Oncology $PSNL Personalis $GH Guardant Health $NEO NeoGenomics $INCY Incyte Non-AI capital flows heavily into precision oncology and screening tech! Smart money triggers tactical limit entries atop long-term FIB volume floors, lock-floating diagnostic monopolies. Early-screening king GH leads the breakout on explosive Shield revenue and full-year guidance upgrades, while path-leader NEO secures NGS pathology profitability and PSNL firms up technical entries. Flanking them, biopharma vanguard INCY hardens its valuation ceiling following key European Opzelura backing. Clinical execution means nothing without scalable adoption and margins. Facing this oncology rotation, are you buying the FIB support floors or holding defensive cash? Drop your execution playbook below!
1 · Reply
B2iDigital
B2iDigital Jul. 2 at 7:32 PM
Profitable as of Q3 2025, Precipio (Nasdaq: $PRPO ) has canceled its ATM facility to move away from the dilutive capital raises common among microcap companies. Precipio, Inc. (Nasdaq: PRPO) did something uncommon for a microcap diagnostics company: it turned profitable, hitting that mark in the third quarter of 2025 and canceling the at-the-market facility it once leaned on. CEO Ilan Danieli framed the shift for microcap investors as a deliberate move toward financial independence. Precipio is a B2i Digital Featured Company. See the company's profile at b2idigital.com/precipio-inc-1 and follow Precipio on X, LinkedIn, and Facebook. "One of the most important things for us as a company to achieve in 2025 was to become profitable," said Danieli. "A couple years ago we did a capital raise. It wasn't the prettiest one, and our team sat around and said, that's it, we're done, we're not doing anything more. We're going to become financially independent. And we did. So we are profitable as of Q3 of 2025." Elsewhere in the session, Danieli covered: • That Precipio canceled its at-the-market (ATM) facility, a signal to shareholders that it would stop the dilutive financing many microcaps rely on • How a cash-efficient model lets the company fund new products without raising another $5 million and diluting investors each time • Why he believes operating profitably at the company's current scale makes for an attractive long-term business model Precipio is a healthcare biotechnology company focused on cancer diagnostics. Its mission is to address the problem of cancer misdiagnoses by developing diagnostic products and services designed to deliver greater accuracy, improved laboratory workflow, and better patient outcomes. Precipio develops, validates, and clinically uses these technologies in its laboratory before commercializing them as proprietary products for the global laboratory community. More information is at precipiodx.com. Investor inquiries: [email protected], +1-203-787-7888 Ext. 523. Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com. Disclosure: This post is informational only and is not an offer or solicitation regarding any security. See the complete Disclosure at b2idigital.com/disclaimer. B2i Digital is not a broker-dealer or investment adviser. $EXAS, $NTRA, $GH, $XBI
1 · Reply
IN0V8
IN0V8 Jul. 2 at 6:22 PM
$GH buy Guardant Health Inc GH.O: Bernstein raises target price to $200 from $175
0 · Reply
TreyBrown
TreyBrown Jul. 2 at 3:44 PM
$GH has had a fun 30 mins. Anyone else watching this? Not much activity here or on X
1 · Reply
Spicy_Trade
Spicy_Trade Jul. 2 at 1:35 AM
Guardant Health, Inc. ( $GH ) SpicyTrade - Daily Stock Analysis https://youtu.be/Txc8WPB_r-4?si=UMdfgtACaXPWpLN5
0 · Reply
Latest News on GH
Guardant Health resumed with an Outperform at Bernstein

2026-06-26T10:30:56.000Z - 8 days ago

Guardant Health resumed with an Outperform at Bernstein


Guardant Health Transcript: AGM 2026

Jun 17, 2026, 12:30 PM EDT - 17 days ago

Guardant Health Transcript: AGM 2026


Gamehost Shareholders Approve Sale to Pure Casino Entertainment

Jun 12, 2026, 1:25 PM EDT - 22 days ago

Gamehost Shareholders Approve Sale to Pure Casino Entertainment


Guardant Health initiated with an Outperform at RBC Capital

2026-06-11T20:17:58.000Z - 22 days ago

Guardant Health initiated with an Outperform at RBC Capital


Guardant Health announces U.S. FDA approved Guardant360 CDx

2026-06-11T12:21:30.000Z - 23 days ago

Guardant Health announces U.S. FDA approved Guardant360 CDx


Guardant Health management to meet with Piper Sandler

2026-06-10T19:41:08.000Z - 23 days ago

Guardant Health management to meet with Piper Sandler


Guardant Health initiated with a Buy at Goldman Sachs

2026-06-05T08:35:20.000Z - 4 weeks ago

Guardant Health initiated with a Buy at Goldman Sachs


Guardant Health assumed with an Outperform at Wolfe Research

2026-06-01T20:54:41.000Z - 4 weeks ago

Guardant Health assumed with an Outperform at Wolfe Research


Guardant Health to present 38 abstracts at ASCO 2026 meeting

2026-05-28T12:35:12.000Z - 5 weeks ago

Guardant Health to present 38 abstracts at ASCO 2026 meeting

PFE


Guardant Health management to meet with Craig-Hallum

2026-05-27T16:54:18.000Z - 5 weeks ago

Guardant Health management to meet with Craig-Hallum


Blood test added to US colorectal cancer screening options

May 27, 2026, 7:03 AM EDT - 5 weeks ago

Blood test added to US colorectal cancer screening options


Guardant Health Earnings Call Transcript: Q1 2026

May 7, 2026, 4:30 PM EDT - 2 months ago

Guardant Health Earnings Call Transcript: Q1 2026


Guardant Health Earnings release: Q1 2026

May 7, 2026, 4:30 PM EDT - 2 months ago

Guardant Health Earnings release: Q1 2026


Guardant Health Slides: Q1 2026

May 7, 2026, 4:30 PM EDT - 2 months ago

Guardant Health Slides: Q1 2026


Guardant Health Quarterly report: Q1 2026

May 7, 2026, 4:30 PM EDT - 2 months ago

Guardant Health Quarterly report: Q1 2026


Guardant Health to Participate in Upcoming Investor Conferences

Apr 29, 2026, 4:05 PM EDT - 2 months ago

Guardant Health to Participate in Upcoming Investor Conferences


Guardant Health Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 2 months ago

Guardant Health Proxy statement: Proxy filing


Guardant Health Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 2 months ago

Guardant Health Proxy statement: Proxy filing


Guardant Health Earnings Call Transcript: Q4 2025

Feb 19, 2026, 4:30 PM EST - 4 months ago

Guardant Health Earnings Call Transcript: Q4 2025


Guardant Health Annual report: Q4 2025

Feb 19, 2026, 4:30 PM EST - 4 months ago

Guardant Health Annual report: Q4 2025


Guardant Health Earnings release: Q4 2025

Feb 19, 2026, 4:30 PM EST - 4 months ago

Guardant Health Earnings release: Q4 2025


Guardant Health Slides: Q4 2025

Feb 19, 2026, 4:30 PM EST - 4 months ago

Guardant Health Slides: Q4 2025


Guardant Health Transcript: 7th Annual Healthcare Symposium

Nov 14, 2025, 8:50 AM EST - 8 months ago

Guardant Health Transcript: 7th Annual Healthcare Symposium


Guardant Health Earnings Call Transcript: Q3 2025

Oct 29, 2025, 4:30 PM EDT - 8 months ago

Guardant Health Earnings Call Transcript: Q3 2025


Guardant Health Quarterly report: Q3 2025

Oct 29, 2025, 4:30 PM EDT - 8 months ago

Guardant Health Quarterly report: Q3 2025


Guardant Health Earnings release: Q3 2025

Oct 29, 2025, 4:30 PM EDT - 8 months ago

Guardant Health Earnings release: Q3 2025


Guardant Health Slides: Q3 2025

Oct 29, 2025, 4:30 PM EDT - 8 months ago

Guardant Health Slides: Q3 2025


Intelligent_investor_
Intelligent_investor_ Jul. 4 at 3:26 PM
$TEM My screener tells me Tempus AI is a buy. So I will be buying 🙉 $GH $NTRA
0 · Reply
Snozz
Snozz Jul. 4 at 3:58 AM
$GH Shield Multi-Cancer Detection to be offered in India. Looks like under license for 10 different cancers. https://www.indiatoday.in/health/story/multi-cancer-blood-test-india-zydus-apollo-shield-mcd-10-cancers-2939850-2026-07-03
0 · Reply
NasdaqNavigatorrr
NasdaqNavigatorrr Jul. 3 at 9:58 PM
Rotation into $XBI has been strong, but this looks more extended than fresh. Biotech momentum is there, but when everyone crowds the move, risk/reward starts to tighten. We closed $GH Wednesday as balancing the book got tougher.
0 · Reply
WallStreetGrowth
WallStreetGrowth Jul. 3 at 9:04 PM
$GH Bernstein lifts target to $200 from $175 after $UNH agreed to cover Shield, Guardant’s blood-based colorectal cancer screening for adults 45+. Big deal for adoption here — coverage removes a major hurdle. Outperform unchanged.
0 · Reply
WAJeff
WAJeff Jul. 3 at 6:26 PM
Top 50 realized gainer changes: $GH (64.2% ytd) climbed to #37, bumping $CIEN and others down the list. $NXT (28.18% ytd) falls out of the top 50
0 · Reply
MorganHoratio
MorganHoratio Jul. 2 at 9:57 PM
One of the strongest sectors outside of AI right now is Biotech. Oncology $PSNL Personalis $GH Guardant Health $NEO NeoGenomics $INCY Incyte Non-AI capital flows heavily into precision oncology and screening tech! Smart money triggers tactical limit entries atop long-term FIB volume floors, lock-floating diagnostic monopolies. Early-screening king GH leads the breakout on explosive Shield revenue and full-year guidance upgrades, while path-leader NEO secures NGS pathology profitability and PSNL firms up technical entries. Flanking them, biopharma vanguard INCY hardens its valuation ceiling following key European Opzelura backing. Clinical execution means nothing without scalable adoption and margins. Facing this oncology rotation, are you buying the FIB support floors or holding defensive cash? Drop your execution playbook below!
1 · Reply
B2iDigital
B2iDigital Jul. 2 at 7:32 PM
Profitable as of Q3 2025, Precipio (Nasdaq: $PRPO ) has canceled its ATM facility to move away from the dilutive capital raises common among microcap companies. Precipio, Inc. (Nasdaq: PRPO) did something uncommon for a microcap diagnostics company: it turned profitable, hitting that mark in the third quarter of 2025 and canceling the at-the-market facility it once leaned on. CEO Ilan Danieli framed the shift for microcap investors as a deliberate move toward financial independence. Precipio is a B2i Digital Featured Company. See the company's profile at b2idigital.com/precipio-inc-1 and follow Precipio on X, LinkedIn, and Facebook. "One of the most important things for us as a company to achieve in 2025 was to become profitable," said Danieli. "A couple years ago we did a capital raise. It wasn't the prettiest one, and our team sat around and said, that's it, we're done, we're not doing anything more. We're going to become financially independent. And we did. So we are profitable as of Q3 of 2025." Elsewhere in the session, Danieli covered: • That Precipio canceled its at-the-market (ATM) facility, a signal to shareholders that it would stop the dilutive financing many microcaps rely on • How a cash-efficient model lets the company fund new products without raising another $5 million and diluting investors each time • Why he believes operating profitably at the company's current scale makes for an attractive long-term business model Precipio is a healthcare biotechnology company focused on cancer diagnostics. Its mission is to address the problem of cancer misdiagnoses by developing diagnostic products and services designed to deliver greater accuracy, improved laboratory workflow, and better patient outcomes. Precipio develops, validates, and clinically uses these technologies in its laboratory before commercializing them as proprietary products for the global laboratory community. More information is at precipiodx.com. Investor inquiries: [email protected], +1-203-787-7888 Ext. 523. Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com. Disclosure: This post is informational only and is not an offer or solicitation regarding any security. See the complete Disclosure at b2idigital.com/disclaimer. B2i Digital is not a broker-dealer or investment adviser. $EXAS, $NTRA, $GH, $XBI
1 · Reply
IN0V8
IN0V8 Jul. 2 at 6:22 PM
$GH buy Guardant Health Inc GH.O: Bernstein raises target price to $200 from $175
0 · Reply
TreyBrown
TreyBrown Jul. 2 at 3:44 PM
$GH has had a fun 30 mins. Anyone else watching this? Not much activity here or on X
1 · Reply
Spicy_Trade
Spicy_Trade Jul. 2 at 1:35 AM
Guardant Health, Inc. ( $GH ) SpicyTrade - Daily Stock Analysis https://youtu.be/Txc8WPB_r-4?si=UMdfgtACaXPWpLN5
0 · Reply
SwingTraderPro1
SwingTraderPro1 Jul. 2 at 12:24 AM
While AI continues to dominate headlines, Biotechnology is quietly becoming one of the strongest sectors in the market.-2 Top 10 Biotechnology Stocks to Watch: $RXRX $BEAM $XENE $GH $TWST If liquidity starts broadening beyond mega-cap tech, biotech is one of the first areas that tends to catch bid early before it shows up in headlines. Head back to my profile to get the latest trading strategies and market analysis.
0 · Reply
LadyBABA
LadyBABA Jul. 2 at 12:04 AM
$GH well well well
1 · Reply
JasonCO
JasonCO Jul. 1 at 11:07 PM
$GH welp I sold this too early. Fml
1 · Reply
EddieHayes
EddieHayes Jul. 1 at 10:40 PM
52-week breakout tape (07/01) $RAAQ +24% $RFL +15% $GH +14% $ADAG +14% $FATE +12% OSCR+12% BOF +11% CPIX +10% RAAQ leading the pack after IQM Quantum Computers completed its SPAC merger with Real Asset Acquisition Corp, officially listing on Nasdaq. Classic SPAC re-rating flow on a fresh public debut with quantum/AI adjacency narrative catching attention. What stands out here is not just the individual moves, but the breadth of small-cap momentum breaking out across sectors while large caps chop. This is how early risk appetite expansion usually starts, rotation shows up in names most people aren’t watching yet. To my subscribers and future subscribers: when the next bull run starts, this is the type of portfolio performance we are working to build again. The real question is simple: are you positioned early, or reacting late when everything is already moving? Are you going to miss out again?
0 · Reply
Gator5326
Gator5326 Jul. 1 at 9:06 PM
$GH https://u18966101.ct.sendgrid.net/ls/click?upn=u001.4ITdg8fiPHHXRRODKhpNknNKs0V2h8ItR6Q2oQCQKcTyRrxC8ZerlixSyXRNZh4ketL7E2RWkAerRsZCr7TPZyHSCsppSPtyeGddfxO4qyf07WvIfFcDShlqis-2B-2B4bWkZYWCR6ujqBsL8Qy2Onu9Dam9pYRdwFMhppj-2FQD4zfx4gVplv4FznPaUQ48EBUUmwUfxEgoyqMYDDlvxAl9SeWpMeZXGVJW23Rq2OojZkq7apAuijG-2FMtxRgZDjf5XCiwO1rj_n7gaS9t6bMxECCQWPRdwdqPZyOAjF4RSivuNxLLPR-2FSmysoqQW1ClVyewMaUHyr5PXnLg-2BfGbSor9w1GLElWTiEw3tZro1MLP1IzWdS5qPpbfYGAtnJcrhAqCrHeCZaHI2-2Fwa1FKYkm5GESYD7aX0x9wigPVzs62W2eHz2AtpFY2N2GZDz79LK7kR5ifPLgAjlpBrSWabIL84eTU7oeXUDFPVNlQNuTXLrqu0WZJtJHGUZE6i1kkD8cF0s0f9zUDgxwjqZ7Lb-2Fs5uk-2FxtdoxtopfddB-2FurE67mkhEV9MHjOCwliDHsQdtWNcs4j5feaibsQccY9Z34GC-2Fu6fTny3-2B-2BeTyETj0UbDnP21O6PpLirKNBgQuC6crzUEghFfy50EftBLiozc18nm7qnP82DlBTtzIOR04-2BE8Tw-2BtchBF9Ubm6bIZXSy6Vzl3fQdT0aik
0 · Reply
MarketsParadise
MarketsParadise Jul. 1 at 8:46 PM
Small caps heating up, We are seeing some big runners lately. Take a look at ticker DRCT 💎 I believe this is the next monster runner waiting to be found: DRCT 💎 • 600K share float--Nano float! • AI-powered digital advertising & marketing drive • Extremely thin chart • Any sustained buying pressure we look for the 5$+. $WXM $NXL $ALDX $RDDT $GH //..
0 · Reply
Stocktwits
Stocktwits Jul. 1 at 7:51 PM
$GH having another great day - chart courtesy of @Honeystocks
0 · Reply
Honeystocks
Honeystocks Jul. 1 at 7:27 PM
$GH is +14% on the day. Now approaching our upside targets at previous all time highs. Can it push through those levels from 2021? 1 of our long running trade ideas from our members trade ideas chart book.
0 · Reply
G101SPM
G101SPM Jul. 1 at 6:55 PM
SPM PORTFOLIO'S MAJOR CORE POSITION $GH $167.00 +17.97 Legacy Hiolding carries a net cost of $16.49 https://stocktwits.com/G101SPM/message/655082236 BRIEF: Guardant Health confirms its Shield blood test for colorectal cancer screening is now covered for eligible UnitedHealth Group (UNH) members . note: Updated United policy coverage from the largest commercial insurer in the U.S. means 100 million total covered lives have access to the FDA-approved Shield blood test for colorectal cancer (CRC) screening. Shield is the first and only FDA-approved blood test included in both ACS and NCCN guidelines. With rising rates of CRC in younger people, the first major commercial insurer in the U.S. expands Shield coverage to eligible policyholders aged 45 or older.
0 · Reply
WallStreetRadar
WallStreetRadar Jul. 1 at 6:30 PM
$GH shares rallied to a more than 5-year high. The surge comes on the heels of a major catalyst, as UnitedHealth is set to begin offering insurance coverage for Guardant Health's colorectal cancer test starting August 1.
0 · Reply
MonkeyBananaGenius
MonkeyBananaGenius Jul. 1 at 5:46 PM
$GH massive move lately. Trimmed a bit more for over 100% gains. Wow
5 · Reply
WAJeff
WAJeff Jul. 1 at 5:33 PM
$GH $NTRA Very strong
0 · Reply